Financial Toxicity as Drugs Move Earlier into Treatment Paradigm and How This Relates to Disparities in Treatment Patterns

CME Available: https://auau.auanet.org/node/35729

Moderator: Jay D. Raman, MD, FACS

Co-Hosts: Sarah Psutka, MD, MS

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Define the magnitude of financial toxicity/economic implications across GU malignancies currently.

2. Forecast the potential changes/increases in financial burden associated with moving systemic therapies earlier in treatment paradigms for patients with GU malignancies.

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

Astellas

AstraZeneca

Bayer

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck & Co., Inc.

Pfizer, Inc.